ClinicalTrials.gg

Program

ECC4703

A development code. Also written as “ECC4703 F0 formulation”, “ECC4703 F1 formulation” and “ECC4703 F2 formulation”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Liver Diseases · Fatty Liver · Obesity, led by Eccogene.

Furthest: phase 2, since Dec 15, 20255 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eccogene54 open or runningphase 2since Dec 15, 2025Sep 13, 2022Dec 2026phase 1 · NCT07726368

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 13, 2022First study: early phase 1 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT05552274 · 75 enrolled · United States
  2. Dec 15, 2025Phase 2 study in Liver DiseasesPhase 2 reachedNCT07288138 · 160 planned · United States
  3. Dec 30, 2025Phase 1 study in Metabolic Dysfunction-Associated SteatohepatitisNCT07334080 · 72 planned · Australia
  4. Mar 5, 2026Phase 2 study in ObesityNCT07505303 · 151 enrolled · United States
  5. Jul 13, 2026Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT07726368 · 40 planned · Australia

Ahead

  1. Dec 2026Primary completion: phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT07726368
  2. Apr 2027Primary completion: phase 1 study in Metabolic Dysfunction-Associated SteatohepatitisNCT07334080
  3. Sep 15, 2027Primary completion: phase 2 study in Liver DiseasesNCT07288138

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07726368Non-alcoholic Fatty Liver Disease · Australia1RecruitingDec 202640
NCT07505303Obesity · United States2Active, not recruitingOct 15, 2026151
NCT07334080Metabolic Dysfunction-Associated Steatohepatitis · Australia1RecruitingApr 202772
NCT07288138Liver Diseases · United States2RecruitingSep 15, 2027160
NCT05552274Non-alcoholic Fatty Liver Disease · United StatesEarly 1CompletedOct 26, 202375

How it is read

Names in the registry

  • “ECC4703”, 5 entries
  • “ECC4703 F0 formulation”, 1 entry
  • “ECC4703 F1 formulation”, 1 entry
  • “ECC4703 F2 formulation”, 1 entry
  • “ECC4703 F3 formulation”, 1 entry

Codes read as this program: ECC4703.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.